Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
24.98
-0.63 (-2.46%)
Streaming Delayed Price
Updated: 1:57 PM EDT, Aug 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
540,466
Open
25.45
Bid (Size)
24.95 (100)
Ask (Size)
24.99 (400)
Prev. Close
25.61
Today's Range
24.78 - 25.90
52wk Range
18.29 - 39.89
Shares Outstanding
70,814,462
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy
↗
August 20, 2026
Ultragenyx Pharmaceutical (NASDAQ:RARE) said the U.S. Food and Drug Administration has approved GENGLYCOS, also known as DTX401, for glycogen storage disease type 1A, or GSD1A. The approval marks the...
Via
MarketBeat
Performance
YTD
+5.8%
+5.8%
1 Month
+0.3%
+0.3%
3 Month
+9.3%
+9.3%
6 Month
+8.5%
+8.5%
1 Year
-22.0%
-22.0%
More News
Read More
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
August 19, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx (RARE) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
Via
The Motley Fool
Topics
Earnings
Ultragenyx (NASDAQ:RARE) Q2 Beats Estimates, Reaffirms Guidance as Shares Rise
↗
August 04, 2026
Via
Chartmill
Ultragenyx Pharma (NASDAQ:RARE) Dips After Q1 Miss as Pipeline Catalysts Loom
↗
May 05, 2026
Via
Chartmill
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
↗
August 04, 2026
Via
MarketBeat
Topics
Earnings
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
August 04, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
July 28, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
July 08, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
June 03, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
↗
May 30, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
May 06, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
May 05, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
April 29, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 24, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
April 06, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
April 06, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 06, 2026
From
Schall Law
Via
GlobeNewswire
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
April 03, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
April 03, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
Frequently Asked Questions
Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?
Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?
Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?
The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market
What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?
The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 24.98
When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?
The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 08/31/26 01:57 PM ET
What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?
The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.77B
How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?
Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
